BCL2L1 and acute myeloid leukemia: The study of “BH3 mimetic” SMIs has led to the development of inhibitors, such as venetoclax (an United States Food and Drug Administration [US FDA]‐approved BCL‐2 specific‐inhibitor for CLL and AML), navitoclax (BCL‐2/BCL‐XL dual inhibitors), or BCL‐XL specific inhibitors.98, 99